Intuitive Surgical: A Growth Story Being Repriced, Not Broken

Intuitive Surgical beat Q2 estimates but saw shares plunge 14% as premium valuation met tempered procedure growth guidance. Analysts remain bullish with average $523 target.

Intuitive Surgical delivered a second-quarter earnings beat that would make most companies envious — revenue of $2.89 billion, up 18.5% year over year, and adjusted earnings per share of $2.80 that sailed past the analyst consensus of $2.48 by nearly 12%. Yet the stock promptly shed 14% in a matter of days, touching a 52-week low of €289.05 on July 23 before closing Friday at €296.35. The market’s reaction has little to do with the company’s underlying health and everything to do with the expectations baked into a premium valuation.

The disconnect is stark. Global procedure volumes rose 16%, with da Vinci procedures climbing 15% and the Ion platform surging 36%. The installed base of robotic systems continues to expand at double-digit rates, underpinning a recurring revenue stream from instruments, accessories, and service contracts that accounts for roughly 75% of total sales. Hardware sales, by contrast, make up only a quarter of the business — meaning the company’s financial engine is far more resilient than a single quarter’s procedure-growth guidance might suggest.

What spooked investors was not the numbers themselves but the nuance in the outlook. Management reaffirmed its 2026 da Vinci procedure growth forecast of 13.5% to 15.5% while nudging expectations toward the middle of that range. That signals a deceleration from 17% growth in the first quarter to 15% in the second — a moderation that, for a stock trading at premium multiples, was enough to trigger a sharp revaluation. William Blair summed it up succinctly: the decline reflects elevated expectations, not a deterioration in long-term prospects.

The analyst community remains broadly constructive despite the rout. Of 28 ratings tracked, 21 are buys, six are holds, and only one is a sell. The average price target stands at roughly $523, implying significant upside from current levels. William Blair maintained its "Outperform" rating even after trimming its target, pointing to two identifiable headwinds: rising competition in China and a decline in U.S. health insurance enrollment through the Affordable Care Act marketplace, which fell from 22.1 million to 19.2 million after expanded premium subsidies expired. Both factors could dampen demand for elective surgeries in the near term, but neither threatens the core business model.

Other firms followed suit with reduced but still bullish targets. Baird cut its price target to $500 with an "Outperform" rating, Bank of America lowered to $515, and Mizuho settled at $500 with a neutral stance. The gulf between these targets and the current share price — roughly 45% above Friday’s close — suggests that many analysts see the sell-off as overdone.

Adding to the narrative of competitive pressure, Johnson & Johnson received De Novo clearance from the FDA for its OTTAVA surgical robot, described as the world’s first operating-table-integrated soft-tissue robotics platform. The system reduces floor space in the OR by 30% to 50% compared with conventional robots and will launch commercially in select U.S. hospitals. While Intuitive Surgical has long dominated the robotic surgery market — projected to grow from roughly $170 billion today to over $250 billion by 2030 — the arrival of a credible rival from a deep-pocketed competitor like J&J introduces a new variable that investors must weigh.

Technical indicators paint a picture of exhaustion rather than impending collapse. The relative strength index sits at 31.9, firmly in oversold territory. The stock closed Friday just 2.53% above its 52-week low, a level that historically has often marked capitulation rather than the start of a fresh downtrend. Year to date, Intuitive Surgical is down 39.42%, a brutal correction for a company that continues to grow revenue in the high teens and expand its installed base.

Institutional behavior offers a mixed signal. Bank of Nova Scotia increased its position by 13.9% in the first quarter, while insiders including director Amy Ladd and senior employee Iman Jeddi sold shares at prices of $473.46 and $420.55 respectively — well above current levels. That divergence is common during periods of sentiment-driven selling, but it underscores the tension between long-term conviction and short-term uncertainty.

The real debate for investors is whether the slowdown in da Vinci procedure growth is a temporary digestion phase after years of rapid expansion or the beginning of a structural shift. Headwinds are real: the ACA enrollment decline, GLP-1 drug adoption potentially reducing demand for certain surgeries, a Class II recall on some da Vinci components, and an FDA safety warning on a stapler device. But none of these individually — or even collectively — dismantle the company’s fundamental competitive advantage. The installed base continues to grow, recurring revenue streams remain intact, and the addressable market for robotic surgery is still in its early innings.

What has happened to Intuitive Surgical’s stock is a classic unwinding of a premium rating. A company that was priced for perfection delivered merely excellent results, and the market responded by repricing the equity. The business itself is not broken. For patient investors willing to look past the noise around ACA enrollment and competitive threats, the risk-reward calculus is shifting increasingly in their favor.